arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

BioStem Technologies, Inc.

BSEM

$3.09 ▼ -0.79 (-20.26%) at close

6 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

insights

Verdict pending

Sync financial data to generate a health grade for this company.

auto_awesome

Analytical Summary

Review the statement evidence below to form a view on BSEM.

Market Cap $53.5M

Dividend Yield —

Revenue Growth -27.9%

Op. Margin -106.3%

ROIC -30.4%

FCF / Share —

Trailing P/E —

Price / Book 2.0x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Sep 30, 2026.

6-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$7.90M

↓ -27.9% —

Net Income Profit after all expenses

$-8.97M

↓ -84631.8% —

Operating Margin Operating profit as % of sales

-106.3%

↓ -10439.8% —

Long-Term Debt Long-term obligations

$0.00

— —

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Revenue Growth YoY (%)	-27.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-449%)	—	—	—	—	—

💰 Are margins durable? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Operating Margin (%) (%)	-106.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-809%)	—	—	1.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-93%)	—	—
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	94.0% Weak Weak Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	-113.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1046%)	—	—	0.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-99%)	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Return on Invested Capital (%)	-30.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	0.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-17.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-32.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-317%)	—	—	0.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-100%)	—	—

⚖️ Is the balance sheet risky? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Debt to Equity (x)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—	—
Net Debt (USD)	$-6.96M	—	$-29.55M	—	—	—
Debt / EBITDA (x)	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Revenue per Share (USD)	$0.46	—	—	$0.66	—	—
Basic EPS, GAAP (USD)	$-0.52	—	—	$0.00	—	—
Book Value per Share (USD)	$1.55	—	$2.33	$2.83	—	—
Tangible Book Value per Share (USD)	$1.46	—	$2.31	$2.83	—	—
Basic Weighted Avg Shares (shares)	17.33M	—	—	16.71M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Working Capital (USD)	$-421.29K	—	$33.62M	—	—	—
LT Debt (USD)	$0.00	—	$0.00	—	—	—
Total Equity (USD)	$27.61M	$31.87M	$39.14M	$47.23M	$46.09M	$40.02M

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-Q ↗
Sales/Revenue/Turnover (USD)	$7.90M	—	—	$10.96M	—	—
Depreciation Expense (USD)	$35.99K	—	—	$29.87K	—	—
Net Income, GAAP (USD)	$-8.97M	—	—	$10.61K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago

BioStem Technologies, Inc.

Analytical Summary

6-Year Financial Trajectory

Statement lens

Benchmark Lens

Compare BSEM with peers